Medications like liraglutide and exenatide offer weight loss and glycemic control benefits, but GLP-1s superior efficacy in reducing major adverse cardiovascular events makes it a preferred choice for high-risk obese patients
Unlike dual-agonists such as Tirzepatide, it targets three key receptors simultaneously: GLP-1, GIP, and Glucagon
Chronic infusion of MG induces type 2 diabetes and MG is considered as a possible mediator of hyperglycemia-induced type 2 diabetes 5
Within the first week or two, some individuals may notice slight changes, such as feeling fuller more quickly or a mild reduction in appetite, but these effects typically become more pronounced as the dose is gradually increased
Clinical trial data shows that burping rates vary by drug and dose: Ozempic injection (semaglutide): Burping reported in 3% of patients at the 0.5 mg dose and 1% of patients at the 1 mg dose Wegovy injection (semaglutide): Burping reported in 7% of adults at the 2.4 mg dose Mounjaro and Zepbound (tirzepatide): Burping reported in 25% of patients across doses (Source: Drugs.com) These numbers likely underestimate real-world prevalence, as sulfur burps are often underreported in clinical trials or described under broader terms like belching or eructation. Some patients avoid mentioning it to their doctors out of embarrassment, as well
Key findings More than half of GLP-1 users, 52%, report that they spend less money on dining out since starting the medications
